Apr 12 |
Pharvaris files for automatic mixed securities shelf
|
Apr 12 |
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
|
Apr 10 |
Pharvaris reports Q4 results
|
Apr 10 |
Pharvaris appoints David Nassif as chief financial officer
|
Apr 10 |
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Apr 10 |
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
|
Apr 4 |
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
|
Mar 18 |
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
|
Mar 6 |
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
|
Mar 5 |
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
|